title: The role of genomics in the management of advanced bladder cancer.
abstract: Advanced bladder cancer (ABC) is an aggressive malignancy with a poor prognosis. For the last 30 years, the standard of care for this disease has consisted of combination chemotherapy with a platinum-containing regimen as first-line therapy. Cisplatin is the most active cytotoxic agent against bladder cancer, but because of competing comorbidities, many patients are ineligible for this agent and instead receive carboplatin. The two-drug regimen of cisplatin and gemcitabine was found to be better tolerated and have comparable efficacy as the four-drug regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in a randomized study of patients with advanced disease. Therefore, cisplatin (or carboplatin) and gemcitabine is the most commonly used first-line regimen in this setting. No agents have been approved by the Food and Drug Administration (FDA) for second-line therapy in ABC. If patients are eligible for additional systemic treatment at the time of progression, options include single-agent therapy such as a taxane or pemetrexed, though given the lack of standard approaches participation in a clinical trial should be strongly encouraged. Recent molecular characterization of ABC reveals significant genetic heterogeneity and actionable genomic alterations in the majority of tumors. Emerging therapies may effectively target known molecular drivers of ABC, including the FGFR2, EGFR/HER2, VEGF, MET, and PI3/AKT/mTOR pathways. Reports of dramatic and prolonged responses to targeted therapy provide additional support for the use of genome sequencing in the rationale selection of treatment for subsets of patients. The current focus of clinical trial development is to design molecularly driven studies that "match" tumors with driver mutations and appropriate targeted therapies rather than a "one-size-fits-all" approach based on clinical and pathologic parameters of disease. The hope of patients and clinicians alike is that this therapeutic approach combined with novel agents may usher in a new era of effective treatments for patients with ABC.
authors: Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center School of Medicine and Dentistry, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA, elizabeth_guancial@urmc.rochester.edu.
authors: Elizabeth A
authors: EA
authors: Guancial
authors: Jonathan E
authors: JE
authors: Rosenberg
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D023281:Genomics / Q000379:methods*; D006801:Humans; D009154:Mutation / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics*; D010597:Pharmacogenetics; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins
references: Nat Rev Urol. 2014 Jul;11(7):400-10
references: 24960601
references: Lancet Oncol. 2012 Aug;13(8):810-6
references: 22819172
references: Urol Oncol. 2009 Jul-Aug;27(4):391-9
references: 18534874
references: BJU Int. 2014 Mar;113(3):429-36
references: 24053564
references: Eur Urol. 2011 Aug;60(2):350-7
references: 21640482
references: Hum Mol Genet. 2014 Apr 15;23(8):1964-74
references: 24270882
references: Hum Mol Genet. 2013 Feb 15;22(4):795-803
references: 23175443
references: J Clin Oncol. 2014 Jun 20;32(18):1895-901
references: 24821881
references: Curr Opin Oncol. 2014 May;26(3):305-20
references: 24685646
references: BMC Med Genomics. 2012 Sep 06;5:40
references: 22954303
references: Nat Rev Clin Oncol. 2013 Oct;10(10):557-70
references: 23982523
references: Urol Oncol. 2014 May;32(4):391-5
references: 24508282
references: Histopathology. 2013 Apr;62(5):788-98
references: 23425286
references: Ann Oncol. 2012 Oct;23(10):2663-70
references: 22473592
references: Clin Transl Oncol. 2014 Jan;16(1):102-6
references: 23606355
references: Mol Med. 2011 May-Jun;17(5-6):478-85
references: 21308147
references: Clin Genitourin Cancer. 2013 Dec;11(4):477-83
references: 23891158
references: J Clin Oncol. 2011 Jun 10;29(17):2432-8
references: 21555688
references: Clin Cancer Res. 2012 Mar 1;18(5):1323-33
references: 22228636
references: Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):E672-81
references: 24469795
references: Cancer Discov. 2014 May;4(5):546-53
references: 24625776
references: Nat Genet. 2013 Dec;45(12):1459-63
references: 24121792
references: Cancer. 2006 Aug 1;107(3):506-13
references: 16773629
references: Ann Oncol. 2014 May;25(5):974-9
references: 24631944
references: Curr Opin Urol. 2013 Sep;23(5):472-8
references: 23907505
references: Mol Cancer Ther. 2007 Jan;6(1):299-308
references: 17218637
references: Mol Cancer Res. 2014 May;12(5):703-13
references: 24554781
references: Nat Genet. 2013 Dec;45(12):1464-9
references: 24121791
references: Nature. 2014 Mar 20;507(7492):315-22
references: 24476821
references: Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13086-91
references: 17666531
references: Mod Pathol. 2014 Feb;27(2):271-80
references: 23887298
references: Cancer. 2009 Sep 15;115(18):4090-5
references: 19536901
references: Ann Oncol. 2012 Feb;23(2):406-10
references: 21543626
references: J Clin Oncol. 2013 Feb 20;31(6):724-30
references: 23341513
references: J Clin Oncol. 2012 Jan 20;30(3):282-90
references: 22162589
references: BJU Int. 2013 Aug;112(4):462-70
references: 23551593
references: J Clin Oncol. 2013 Sep 1;31(25):3133-40
references: 23897969
references: J Clin Oncol. 1992 Jul;10(7):1066-73
references: 1607913
references: Invest New Drugs. 2011 Oct;29(5):1045-9
references: 20191303
references: Anticancer Drugs. 2013 Apr;24(4):422-5
references: 23407060
references: Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5
references: 24520177
references: J Clin Oncol. 2014 Jun 20;32(18):1889-94
references: 24821883
references: Nat Genet. 2013 Dec;45(12):1428-30
references: 24121789
references: CA Cancer J Clin. 2013 Jan;63(1):11-30
references: 23335087
references: Clin Genitourin Cancer. 2013 Jun;11(2):175-81
references: 23228446
references: Cancer Epidemiol. 2013 Jun;37(3):219-25
references: 23485480
references: Hum Pathol. 2012 Oct;43(10):1590-5
references: 22406363
references: Cancer. 2014 Jun 1;120(11):1630-8
references: 24733278
references: J Clin Oncol. 2012 Feb 20;30(6):647-60
references: 22271477
references: Nat Rev Cancer. 2005 Sep;5(9):713-25
references: 16110317
references: J Clin Oncol. 2010 Mar 10;28(8):1373-9
references: 20142593
references: Mol Cancer Res. 2014 Jul;12(7):1042-54
references: 24784839
references: Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
references: 15939524
references: J Clin Oncol. 2009 Sep 20;27(27):4454-61
references: 19687335
references: J Clin Oncol. 2011 Apr 20;29(12):1525-30
references: 21422406
references: Anticancer Res. 2013 Jun;33(6):2381-90
references: 23749886
references: Future Oncol. 2013 Nov;9(11):1637-51
references: 24156324
references: Science. 2012 Oct 12;338(6104):221
references: 22923433
references: J Clin Oncol. 2005 Jul 20;23(21):4602-8
references: 16034041
references: Ann Oncol. 2013 Sep;24(9):2414-21
references: 23897706
references: J Clin Oncol. 2006 Dec 10;24(35):5519-27
references: 17158537
references: Cancer Cell. 2014 Feb 10;25(2):152-65
references: 24525232
references: Nat Genet. 2011 Aug 07;43(9):875-8
references: 21822268
references: Cancer Med. 2014 Aug;3(4):835-44
references: 24846059
references: J Clin Oncol. 2007 Jun 1;25(16):2218-24
references: 17538166
references: Pathology. 2014 Jun;46(4):274-82
references: 24798156
references: Expert Opin Ther Targets. 2012 Jun;16(6):553-72
references: 22530990
references: Eur J Cancer. 2010 Jan;46(1):207-15
references: 19914824